^
Association details:
| Biomarker: | CEACAM5 overexpression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) + tusamitamab ravtansine (SAR408701) (Microtubule inhibitor, CEACAM5-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Published date:
10/16/2023
Excerpt:
CARMEN-LC04 is an open-label phase 2 study (NCT04394624) assessing combination tusa rav 100 mg/m2 every 2 weeks (Q2W) + ram 8 mg/kg Q2W in patients with mNSQ NSCLC and high CEACAM5 expression (≥2+ intensity in ≥50% of tumor cells by immunohistochemistry)....Tusa rav + ram showed encouraging efficacy.
Trial ID:
